Category: Drugs/Drug Classes

All Podcast Categories
S4-23.2 - The Future of AI-Assisted Digital Pathology and NITs

S4-23.2 – The Future of AI-Assisted Digital Pathology and NITs

Stephen Harrison speaks with Louise Campbell and Roger Green about the Nature Medicine published paper, Challenges and Opportunities in NASH Drug Development. The group considers what exactly is moving the field rapidly forward. The focus of this conversation considers the future of AI-assisted digital pathology, NITs and screen fail rates.

S4-23.1 - Obeticholic Acid: Is the Juice Worth the Squeeze?

S4-23.1 – Obeticholic Acid: Is the Juice Worth the Squeeze?

Stephen Harrison speaks with Louise Campbell and Roger Green about challenges and opportunities in NASH drug development. This conversation features Stephen’s take on the recent outcome of the FDA ADCOM meeting for obeticholic acid (OCA) as a treatment for pre-cirrhotic fibrosis due to NASH.

S4-23 - Stephen Harrison on Challenges and Opportunities in NASH Drug Development

S4-23 – Stephen Harrison on Challenges and Opportunities in NASH Drug Development

Stephen Harrison speaks with Louise Campbell and Roger Green about challenges and opportunities in NASH drug development. The group dives deep into a range of topics including drugs with strong metabolic foundations, the state of histopathology, clinical trial design and screen fail rates, FDA ADCOM on obeticholic acid and much more.

S4-22 - PART 1: FDA ADCOM Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis Due to NASH

S4-22 – PART 1: FDA ADCOM Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis Due to NASH

Donna Cryer joins Jörn Schattenberg and Roger Green for a session which draws from raw reflections on the recent FDA Advisory Committee meeting and its outcome for obeticholic acid. The group remains focused on a critical message that looks down the path forward for the liver community and meeting patient needs. Stay tuned for more coverage as SurfingNASH continues to meet with other KOLs and stakeholders to discuss the event and its implications.

S4-20.6 - From the Vault: Discussing NITs and Final Thoughts on NAFLD Summit

S4-20.6 – From the Vault: Discussing NITs and Final Thoughts on NAFLD Summit

Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation From the Vault, the group discusses NITs and what will change between now and when this conference convenes next year.

S4-20.5 - Harnessing the Strengths of the Patient Advocate Community

S4-20.5 – Harnessing the Strengths of the Patient Advocate Community

In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. This final conversation elaborates on the myriad abilities possessed by the patient community which can be deployed to the fight against Fatty Liver diseases.

Experience Nudge Learning! Interested in a new way of learning?